You know, we’re really asking our patients to endure ongoing treatment, not only having to continue to come into my office and get the treatments, which at this point are intravenous infusions, but also the cumulative toxicity. I mean, you can imagine a therapy of up to three years’ duration that really changes your life, that changes the life for your family who have to bring you in for treatment...
You know, we’re really asking our patients to endure ongoing treatment, not only having to continue to come into my office and get the treatments, which at this point are intravenous infusions, but also the cumulative toxicity. I mean, you can imagine a therapy of up to three years’ duration that really changes your life, that changes the life for your family who have to bring you in for treatment. And what I think this allows us to do is we don’t have to shy away or we don’t have to reserve these treatments for patients who are younger. We can, when I’m counseling a patient and discussing with her the benefits of undertaking this three-year sort of journey with me, I can really do so with full confidence that the patient will enjoy the benefits of her treatment, keeping her disease-free longer. And if her disease recurs, based upon this data, we can actually share with the patient and her family that this will not impair her ability to have second-line treatment. In other words, the toxicity will not be so significant because of this maintenance treatment, that she will be able to benefit from second-line treatment and potentially third-line treatment without any undue delays or undue inability because of cumulative toxicity to be treated in the future. And that she will have, regardless of her age, she will continue to enjoy the benefits of the addition of this treatment, even though the maintenance treatment is three years in duration at this point in time.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
